Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel-R Hanauske

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Oncology (Williston Park, N.Y.)|January 20, 2005
Translational research with pemetrexed in breast cancerAxel R Hanauske
Seminars in Oncology|July 3, 2002
Pemetrexed: translational research in breast cancerAxel R Hanauske
Oncology (Williston Park, N.Y.)|January 20, 2005
Overview of phase I/II pemetrexed studiesAxel R Hanauske, Christian Dittrich, Jorge Otero
European Journal of Cancer (Oxford, England : 1990)|January 19, 2010
First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumoursClemens Unger, Wolfgang Berdel, Axel-R Hanauske, et al.
Anti-Cancer Drugs|February 1, 2007
Antiproliferative activity of Titanocene Y against tumor colony-forming unitsOlaf Oberschmidt, Axel R Hanauske, Clara Pampillón, et al.
Anti-Cancer Drugs|October 14, 2005
Activity of [1,2-di(cyclopentadienyl)-1,2-di(p-N,N-dimethylaminophenyl)-ethanediyl] titanium dichloride against tumor colony-forming unitsOlaf Oberschmidt, Axel-R Hanauske, Franz-Josef K Rehmann, et al.
Anti-Cancer Drugs|February 1, 2007
Antitumor activity of Titanocene Y against freshly explanted human breast tumor cells and in xenografted MCF-7 tumors in micePhilipp Beckhove, Olaf Oberschmidt, Axel R Hanauske, et al.
Current Drug Targets|October 21, 2009
Pharmacological aspects of the enzastaurin-pemetrexed combination in non-small cell lung cancer (NSCLC)Elisa Giovannetti, Richard Honeywell, Axel R Hanauske, et al.
Seminars in Oncology|February 7, 2003
Pemetrexed safety and dosing strategyClet Niyikiza, Axel-R Hanauske, James J Rusthoven, et al.
Investigational New Drugs|October 29, 2008
Pemetrexed combined with paclitaxel: a dose-finding study evaluating three schedules in solid tumorsAxel-R Hanauske, Herlinde Dumez, Martine Piccart, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Oncology (Williston Park, N.Y.)|January 20, 2005
Translational research with pemetrexed in breast cancerAxel R Hanauske
Seminars in Oncology|July 3, 2002
Pemetrexed: translational research in breast cancerAxel R Hanauske
Oncology (Williston Park, N.Y.)|January 20, 2005
Overview of phase I/II pemetrexed studiesAxel R Hanauske, Christian Dittrich, Jorge Otero
European Journal of Cancer (Oxford, England : 1990)|January 19, 2010
First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumoursClemens Unger, Wolfgang Berdel, Axel-R Hanauske, et al.
Anti-Cancer Drugs|February 1, 2007
Antiproliferative activity of Titanocene Y against tumor colony-forming unitsOlaf Oberschmidt, Axel R Hanauske, Clara Pampillón, et al.
Anti-Cancer Drugs|October 14, 2005
Activity of [1,2-di(cyclopentadienyl)-1,2-di(p-N,N-dimethylaminophenyl)-ethanediyl] titanium dichloride against tumor colony-forming unitsOlaf Oberschmidt, Axel-R Hanauske, Franz-Josef K Rehmann, et al.
Anti-Cancer Drugs|February 1, 2007
Antitumor activity of Titanocene Y against freshly explanted human breast tumor cells and in xenografted MCF-7 tumors in micePhilipp Beckhove, Olaf Oberschmidt, Axel R Hanauske, et al.
Current Drug Targets|October 21, 2009
Pharmacological aspects of the enzastaurin-pemetrexed combination in non-small cell lung cancer (NSCLC)Elisa Giovannetti, Richard Honeywell, Axel R Hanauske, et al.
Seminars in Oncology|February 7, 2003
Pemetrexed safety and dosing strategyClet Niyikiza, Axel-R Hanauske, James J Rusthoven, et al.
Investigational New Drugs|October 29, 2008
Pemetrexed combined with paclitaxel: a dose-finding study evaluating three schedules in solid tumorsAxel-R Hanauske, Herlinde Dumez, Martine Piccart, et al.
Pageof 2